Stockreport

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Agenus Inc.  (AGEN) 
Last agenus inc. earnings: 3/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: agenusbio.com/investors
PDF Study highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory diseaseData expected to inform immune modulation, treatment sequencing, and d [Read more]